Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Ajax, Canada Clinical Trials

A listing of Ajax, Canada clinical trials actively recruiting patients volunteers.

RESULTS

Found (6) clinical trials

The purpose of this study is to evaluate the efficacy of each strength of INCB018424 cream once daily or twice daily in subjects with atopic dermatitis compared with vehicle cream.

Phase

0.61 miles

Learn More »

The Safety Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream 0.3% or ARQ-151 cream 0.15% or vehicle cream is applied once daily for 84 days to subjects with chronic plaque psoriasis involving between 2 and 20% body surface area.

Phase

0.61 miles

Learn More »

An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

This is a multicenter and open-label (participants and researchers are aware of the treatment that participants are receiving) study that consists of 4 phases; a Prescreening Phase for biomarker evaluation only, a Screening Phase, a Treatment Phase (Cycle 1 Day 1 and will continue until the study drug is discontinued), ...

Phase

8.34 miles

Learn More »

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

Phase

8.42 miles

Learn More »

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

A study to evaluate the safety of Nivolumab in patients with advanced or metastatic non-small cell lung cancer

Phase

8.42 miles

Learn More »

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to assess and compare the clinical benefit rate in patients with metastatic castrate-resistant prostate cancer and poor prognostic factors treated with cabazitaxel or novel hormonal agents (abiraterone or enzalutamide) as initial therapy, to determine which treatment is most active in this population. Clinical benefit ...

Phase

8.42 miles

Learn More »